Sands, J., Henry, J. T., Spira, A. I., Mahadevan, D., Meador, C. B., Weiss, J., Naqash, A. R., Chan, J. A., Beltran, H., McGregor, G. H., Laeufle, R., Zou, H. (2025). An open-label, multicenter, phase 1/2 study of peluntamig (PT217), an anti-DLL3/anti-CD47 bispecific antibody, in patients with DLL3-expressing cancers such as SCLC, LCNEC and EP-NEC (SKYBRIDGE study).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.tps8128